» Articles » PMID: 12693439

Predictors of Risk of Nonadherence in Outpatients with Schizophrenia and Other Psychotic Disorders

Overview
Journal Schizophr Bull
Specialty Psychiatry
Date 2003 Apr 16
PMID 12693439
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the course of adherence to medication recommendations in 162 patients with psychotic disorders in ambulatory treatment. Data were collected using the clinic's outcome assessment program, maximizing the generalizability of the study. Patients initially adherent to their medication regimens maintained their adherence for an average of 13.3 months. Patients initially nonadherent developed adherence after an average of 5.6 months of treatment. Demographic factors and illness history were unrelated to adherence. This study replicated previous findings of the concurrent association between adherence and global functioning level, substance use, and working alliance with therapist. Cox regression analyses revealed that working alliance, global functioning, and being prescribed clozapine predicted longer maintenance of adherence. Working alliance was the most significant and consistent predictor of adherence to medication recommendations.

Citing Articles

Enhancing physical activity through a relational artificial intelligence chatbot: A feasibility and usability study.

Oh Y, Liang K, Kim D, Zhang X, Yu Z, Fukuoka Y Digit Health. 2025; 11:20552076251324445.

PMID: 40041394 PMC: 11877463. DOI: 10.1177/20552076251324445.


Systematic Review and Meta-analysis of Exercise Interventions for Psychotic Disorders: The Impact of Exercise Intensity, Mindfulness Components, and Other Moderators on Symptoms, Functioning, and Cardiometabolic Health.

Rissmayer M, Kambeitz J, Javelle F, Lichtenstein T Schizophr Bull. 2024; 50(3):615-630.

PMID: 38394386 PMC: 11651296. DOI: 10.1093/schbul/sbae015.


Antipsychotic medication non-adherence and factors associated among patients with schizophrenia in eastern Ethiopia.

Mohammed F, Geda B, Yadeta T, Dessie Y BMC Psychiatry. 2024; 24(1):108.

PMID: 38326836 PMC: 10851518. DOI: 10.1186/s12888-024-05554-0.


Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study.

Margolese H, Boucher M, Therrien F, Clerzius G BMC Psychiatry. 2022; 22(1):773.

PMID: 36482352 PMC: 9733174. DOI: 10.1186/s12888-022-04397-x.


Levels of mental distress over 18 years after entering treatment for substance use disorders: A longitudinal cohort study.

Hjemsaeter A, Bramness J, Drake R, Skeie I, Monsbakken B, Saltyte Benth J Nordisk Alkohol Nark. 2022; 37(4):352-364.

PMID: 35310926 PMC: 8899246. DOI: 10.1177/1455072520947249.